The effects of SUV39H1 knockout on T cell effector functions have demonstrated variability across studies, likely due to differences in disease models (tumor vs. virus), T cell activation methods (TCR vs. CAR), and therapeutic approaches (PD-1 blockade vs. T cell therapy). This evidence concerns the gene PDCD1 and neoplasm.